Kodiak Sciences Inc
KODHealthcare|Biotechnology|USA
$41.28
+1.23 (+3.07%)
Tangible Book
$1.80
Clinical Trials (11)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06996080 A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | Macular Edema Secondary to Inflammation | P3 | Recruiting | 300 | RCT, Double-blind | KSI-101 |
| NCT06556368 A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | Wet Age-related Macular Degeneration | P3 | Active | 675 | RCT, Double-blind | Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept |
| NCT06990399 A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK | Macular Edema Secondary to Inflammation | P3 | Recruiting | 600 | RCT, Double-blind | KSI-101 |
| NCT04611152 A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) | Diabetic Macular Edema | P3 | Terminated | 460 | RCT, Double-blind | KSI-301, Aflibercept |
| NCT04592419 A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) | Macular Edema, Retinal Vein Occlusion | P3 | Completed | 568 | RCT, Double-blind | KSI-301, Aflibercept |
| NCT04049266 A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. | Wet Macular Degeneration | P2P3 | Terminated | 559 | RCT, Double-blind | KSI-301, Aflibercept |
| NCT04964089 A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) | Wet Age-related Macular Degeneration | P3 | Completed | 557 | RCT, Double-blind | KSI-301, Aflibercept |
| NCT04603937 A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) | Diabetic Macular Edema | P3 | Terminated | 459 | RCT, Double-blind | KSI-301, Aflibercept |
| NCT06270836 A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR) | Diabetic Retinopathy | P3 | Completed | 255 | RCT, Double-blind | Tarcocimab |
| NCT05066230 A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) | Non-proliferative Diabetic Retinopathy | P3 | Terminated | 253 | RCT, Double-blind | KSI-301 |
| NCT03790852 Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO | Wet Age-related Macular Degeneration, Retinal Vein Occlusion | P1 | Terminated | 121 | RCT, Open-label | KSI-301 |